Biocon Limited:Hold,Neulasta

From 6 possible late stage players, competition in Neulastabiosimilar narrows to 1-2 players in the near term

    CRL and/or cGMP issues hurting most. We look at Form 83issued to facilities of Intas/Apotex and Biocon/Mylan

    Biosimilar opportunity exciting but facility clearance is a hurdlenear term; Hold with revised TP of INR370 (from INR355)